Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
GEN1057 · 1 trial · 2 indications
| Name | Type | Description |
|---|---|---|
| GEN1057 | DRUG | Intravenous (IV) infusion |
| Premedication | DRUG | IV infusion/orally by mouth. |
GEN1057 is an investigational small molecule being developed for the treatment of advanced malignant solid tumors, including metastatic malignant solid tumors. It is currently in Phase 1 clinical development and has not been approved by regulatory authorities.
GEN1057 targets DR4, a protein also known as death receptor 4. By targeting this protein, the drug is designed to potentially induce apoptosis, or programmed cell death, in tumor cells. This mechanism is being evaluated in the context of advanced solid tumors.
GEN1057 is being developed by Genmab A/S, a biotechnology company listed on the Nasdaq under the ticker symbol GMAB. The company is conducting clinical trials to assess the safety and antitumor activity of this investigational drug.
GEN1057 is in Phase 1 clinical development. It is currently being studied in an early-stage trial to evaluate its safety, tolerability, and preliminary antitumor activity in patients with advanced malignant solid tumors. The drug is not yet approved for commercial use.
GEN1057 is being evaluated in a Phase 1 clinical trial with the identifier NCT06573294. This trial is titled 'Trial to Assess the Safety and Antitumor Activity of GEN1057 in Malignant Solid Tumors' and is currently recruiting participants with advanced or metastatic solid tumors.